MAIA
MAIA Biotechnology, Inc.
Next earnings Aug 10, 2026 · consensus $-0.11 EPS
$1.41
▲ +4.44%$1.41▼ -20.34%
over 1Y
L $0.87EODHDH $2.95
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.4%
1W+4.4%
1M+7.6%
3M+7.6%
YTD-11.9%
1Y-20.3%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Mixed signals in the latest filings.
Revenue (FY2024) $0.00 · FY2024
MAIA Biotechnology, Inc. shows $0.00 in FY2024 revenue, and -942.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$7.79M | -$16.2M | -$20.2M | -$17.0M | -$24.3M |
| Net income | — | — | — | -$23.3M | -$22.4M |
| Diluted EPS | -$2.37 | -$1.75 | -$1.49 | -$1.05 | -$0.70 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$85.5M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-26.2%
FCF yield—
Quality & risk
ROIC (est.)-807.0%
Free cash flow—
Total debt—
Net cash$0.00
Altman Z-Score-16.59 distress
Piotroski F-Score1/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+105.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-05-14). Worth a closer look.
Recent filings
all on EDGAR ↗4Period ending 2026-06-012026-06-02open ↗4Period ending 2026-06-012026-06-02open ↗4Period ending 2026-06-012026-06-02open ↗4Period ending 2026-05-292026-06-01open ↗4Period ending 2026-05-292026-06-01open ↗4Period ending 2026-05-292026-06-01open ↗8-KPeriod ending 2026-05-212026-05-22open ↗DEFA14AFiling2026-05-19open ↗SCHEDULE 13GFiling2026-05-15open ↗8-KPeriod ending 2026-05-142026-05-14open ↗424B5Filing2026-05-14open ↗10-QPeriod ending 2026-03-312026-05-11open ↗
Frequently asked
- Is MAIA Biotechnology, Inc. (MAIA) a buy?
- MAIA currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
- What is MAIA Biotechnology, Inc.'s quality score?
- MAIA scores 43.666666666666664/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001878313, latest 10-Q filed 2026-05-11) · EODHD · as of 6/26/2026, 6:55:06 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.